Over the years, Hengrui Pharma has paid close attention to the treatment status of breast cancer in China, and continued to explore more breast cancer treatment programs. China's first self-developed new highly selective CDK4/6 inhibitor and China's first self-developed HER 1/HER2/HER4 targeted drug provide more treatment options for China doctors and breast cancer patients. In addition, the company currently has a number of innovative drug products in the field of breast cancer treatment, covering a variety of breast cancer subtypes and drugs with different mechanisms of action, involving the indications from the late second line, the late first line and the new auxiliary/auxiliary stage; Hengrui also actively participates in public welfare actions to care for women's health and the popularization of cancer-related knowledge. Relying on its own scientific research advantages and professional knowledge in the field of anti-tumor treatment, Hengrui gathers all forces to promote the scientific development of tumor prevention and treatment.
In the future, Hengrui Pharma will always adhere to the patient-centered, focus on breast cancer and other tumor areas, strengthen the research and development and application of innovative drugs, and constantly provide more and better solutions for the urgent clinical needs, serve healthy China and benefit patients around the world. I hope my answer can help you.